Direct answer. Aortic regurgitation is leakage backward from the aorta into the left ventricle when the aortic valve should be closed. It can arise from valve-leaflet disease or changes in the aortic root, and can be chronic or suddenly severe. The cause, leakage severity, ventricular response and aortic findings guide care. Confidence is high in these distinctions; attributed procedure recommendations are not a financially cleared independent comparison of all valve treatments. NHLBI valve anatomy and types, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
- Leakage differs from aortic stenosis, although both may affect the same valve.
- The aortic root can cause leakage even when the problem is not confined to a leaflet.
- Sudden severe leakage is a different urgency from stable chronic regurgitation.
- Feeling well does not establish normal ventricular size or function in chronic significant disease.
- Medication, surveillance and intervention target different problems; a valve and aortic plan should be explained together.
Evidence summary
| Question | Source role | Conclusion and confidence |
|---|---|---|
| Where does blood return? | Public anatomy | From aorta to left ventricle during relaxation. High confidence. |
| Is the leaflet always the cause? | 2025 cause and imaging guidance | No. Aortic-root and leaflet abnormalities can act separately or together. |
| When is intervention considered? | Attributed current clinical context | Symptoms, ventricular effects, severity, aortic disease and stability matter. |
| Can tablets prove surgery unnecessary? | Care and independent-evidence boundary | No. Associated treatment or symptom relief does not settle the valve indication. |
Confidence is high in the condition distinctions and need for appropriate assessment. The treatment section attributes clinical guidance; it does not certify the funding of every underlying intervention trial. Independent comparative outcome certainty and a supplement replacement regimen were not established by this focused review. A public institution or independent review cannot make a sponsored original trial financially independent.
What it is
When the left ventricle relaxes, the aortic valve should close and help keep blood in the arterial circulation. Regurgitation allows some blood to return to the ventricle. It is also called aortic insufficiency. The word describes leakage, not how urgently someone needs treatment; a small stable finding and a sudden major leak have different implications. NHLBI valve anatomy and types, March2022.
A damaged or differently shaped leaflet can leak. A bicuspid valve, infection and other acquired valve processes can be relevant. The opening and closure can also be affected by enlargement or distortion of the supporting aortic root. Assessment therefore examines both the valve and nearby aorta instead of assuming that every case is a leaflet-only problem. NHLBI valve disease causes, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Chronic regurgitation may be found from a murmur or imaging before symptoms are recognized. Breathlessness, reduced capacity and other symptoms can develop, but they are not specific. Acute severe disease may produce rapidly worsening breathing or circulation without the longstanding enlargement expected in a chronic case. An old reassuring result cannot safely explain a new acute episode. NHLBI valve disease symptoms, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
How it works
In chronic significant leakage, returning blood adds a volume load to the left ventricle. The chamber can enlarge as it adapts, and later its function can deteriorate. Symptoms, size, contraction and leakage severity are related measures but not interchangeable. The aim of review is to recognize the whole trajectory rather than waiting for one symptom to become severe. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Echo is usually the first imaging investigation. It evaluates valve anatomy, the leak, ventricular response and aortic dimensions. MRI or CT can answer selected questions when measurements are uncertain or when aortic or procedural anatomy needs definition. The clinical team interprets findings with blood pressure and other conditions; a single colour jet or measurement is not a complete home severity test. NHLBI valve disease diagnosis, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
A sudden change can have a different cause, including infective endocarditis or aortic dissection. These diagnoses require their own emergency or specialist pathway, rather than treatment based solely on the word regurgitation. Aortic disease may also affect intervention timing independently of the leak’s apparent severity. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
The evidence-based treatments
A stable chronic case can need scheduled symptom and imaging surveillance. The 2025 guideline links intervention discussions to established severity, symptoms, effects on ventricular size or function and associated aortic disease. It also separates acute severe regurgitation, which usually requires immediate specialist surgical assessment according to cause. These are attributed clinical recommendations with explicit financial gaps, not numerical self-screening or personal operation thresholds. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Medicines may address high blood pressure, congestion or another accompanying problem. For selected people in whom surgery is unsuitable, treatment can aim to improve symptoms. The current guidance does not establish that prescribing afterload treatment solely to an asymptomatic person will reliably delay a needed operation. Improvement in symptoms or pressure should be discussed alongside the valve and ventricular findings. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Surgical valve replacement, selected repair or valve-sparing aortic surgery may be considered depending on anatomy and the involved structures. If the aorta also needs treatment, the team should explain whether the operation addresses both problems. Repair suitability depends on the actual valve/root pattern and specialist expertise; avoiding an implant is not an automatic guarantee of durability. NHLBI valve care background, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Catheter replacement for native aortic regurgitation is a selected specialist option, not a simple transfer of all evidence from calcific aortic stenosis. The 2025 guideline discusses appropriate anatomy, surgical suitability and device-specific limitations. This article does not rank products or use manufacturer-related outcomes as its independent verdict. Anyone offered a procedure should hear the alternatives, uncertainties and subsequent monitoring plan. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Supplement and lifestyle evidence
Activity advice should account for the leak, ventricular response and any aortic enlargement. An exercise programme or heavy straining should be discussed with the responsible team when important valve/aortic disease is present. Appropriate nutrition, smoking cessation and treating other cardiovascular risks support general care; no diet or retail supplement is established here to repair a valve or normalize an enlarged aorta. NHLBI valve care background, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
No supplement is established here as a treatment for aortic regurgitation. “Heart support,” improved vessel relaxation, a changed blood marker and fewer clinical events are different claims. The cited source set does not provide a fully financially screened trial basis for replacing diagnosis or prescribed care. Correcting a clinician-confirmed deficiency is a separate indication; a retail blend is not a diagnostic test or an emergency treatment.
What works and what does not
Useful care explains whether the current goal is surveillance, symptom relief, management of an underlying cause or intervention before further structural change. It distinguishes valve leakage from aortic risk and gives a route for new symptoms. A quieter murmur, lower blood pressure or less breathlessness is not by itself proof that all those problems have resolved. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Ask which outcome is being pursued: symptoms, physiological findings, recurrence, hospital admission or survival. A plan should also say how adverse effects and deterioration will be recognized. Personal stories and before-and-after readings cannot separate treatment effects from the natural course, other medicines or selection of patients. Manufacturer or materially conflicted outcome claims do not determine this article’s independent verdict.
Risks and side effects
Severe or rapidly worsening breathlessness, collapse or new concerning chest, back or spreading pain needs emergency assessment. Sudden symptoms should not be treated as a routine fluctuation of an old murmur or stable leak. Fever or systemic illness with new cardiac symptoms also deserves prompt assessment for possible infection and other causes. NHS current national heart valve disease education; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Valve or aortic procedures can cause bleeding, stroke, infection, kidney or cardiac injury, residual leakage and the need for later intervention. A mechanical valve needs a continuing anticoagulation plan; a tissue valve does not mean that every anticoagulant indication disappears. Medicines for accompanying conditions can lower pressure or alter kidney function and require monitoring. NHLBI valve care background, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Important interactions
The clinician should review blood-pressure and rate medicines, diuretics, anticoagulants and supplements together. A medicine needed for another illness may require additional consideration in significant leakage, so do not start or stop it from a general online list. Inform procedural teams about all products and previous implants; pregnancy planning needs a specific prescription and valve review. NHLBI valve disease and pregnancy, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Bring prescription medicines, non-prescription products, recreational drugs and supplements to the same medication review. Product names alone may hide several active ingredients. The prescriber or pharmacist should check the exact combination and kidney function, rather than treating “natural” as a safety category. Never add a second person’s rescue medicine or stop an important prescribed medicine because an internet list mentions a possible interaction.
Who needs assessment
Ask whether the cause is leaflet, root or combined disease; whether leakage is acute or chronic; how severity was established; and what the ventricle and aorta show. Echo, selected MRI/CT and clinical history answer complementary questions. Prior infection, a known connective-tissue condition or a bicuspid valve may change the work-up and follow-up. NHLBI valve disease diagnosis, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Pregnancy planning, a previous valve intervention, kidney disease and anticoagulant use deserve specific review. The current status of the valve matters more than an old diagnostic label. Children with congenital disease need an age-appropriate specialist pathway rather than an adult intervention rule. NHLBI valve disease and pregnancy, March2022.
Clinician-led use and follow-up
Ask which symptoms require earlier contact, when ventricular and aortic imaging will be repeated and which findings could change treatment. After repair or replacement, clarify implant or repair surveillance, anticoagulation and infection-related precautions. There is no personal tablet dose, scan-size threshold or fixed recovery deadline in this guide; the written plan should reflect the actual cause and findings. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
This guide gives no personal drug, device or supplement dose. The appropriate plan depends on the established diagnosis, current stability, other illnesses and local services. Ask for a written explanation of the treatment purpose, warning signs, review schedule and contact route for side effects. Clinical monitoring and informed consent should accompany any change; study exposures are not prescriptions.
Animal and in-vitro evidence
Laboratory work on valve calcification, connective tissue or blood-flow mechanics can help investigate a mechanism. It cannot determine a safe human supplement dose, establish that a calcified valve will reopen, or select an implant for an individual. An animal or cell finding does not replace a clinical assessment of anatomy, severity and complications. No animal or in-vitro result contributes to this guide’s independent clinical verdict.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 16 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
Financial interests include echocardiography and advanced imaging, valve implants, surgical and catheter services, medicines and marketed supplements. Valve-device manufacturers and professional societies can have relevant financial relationships even when the document itself reports no direct industry-development funding. Those routes and unresolved author/trial chains are shown below; no manufacturer or materially conflicted outcome claim establishes this guide’s independent verdict.
The condition has no corporate owner. Medicines, diagnostics, devices, procedures and marketed supplements create different revenue incentives. This describes financial interests rather than misconduct. Funding tier evaluates proximity to the subject; A–D credibility assesses transparency, accuracy incentives and remaining uncertainty. An unresolved link stays unresolved, and a provisional public-information label does not clear the trials behind it.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHLBI valve anatomy and types, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Dated public anatomy and distinctions between stenosis, regurgitation and prolapse. |
| NHLBI valve disease causes, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Dated public inherited and acquired contributor education. |
| NHLBI valve disease symptoms, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Public symptom education; symptoms do not establish severity. |
| NHLBI valve disease diagnosis, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Clinical investigation background; no self-diagnostic thresholds. |
| NHLBI valve care background, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Dated public procedure/adverse-effect background; oversimplified tissue-valve anticoagulation wording not reproduced. |
| NHS current national heart valve disease education | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 1 public education provisional; not a clearance of original studies. | B provisional. Public-service remit and editorial checks support accuracy; simplification, service priorities and incomplete trial-finance tracing limit inference. Role: January 2025 national condition and emergency education; broad prolapse wording not reproduced. |
| Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF | The original guideline states document development was financed entirely by ESC and EACTS without healthcare-industry involvement. ESC institutional revenues nevertheless include life-science and medtech partnerships; EACTS discloses industry/charity grants and an Edwards Lifesciences Foundation partnership. That separate route does not prove Edwards funded this guideline. The official 2025 author declaration report returned 403 and was not read. Article allocation, individual author independence and original device/drug trial chains remain unresolved. | France: ESC, Sophia Antipolis. United Kingdom: EACTS, Windsor, registered England and Wales; OUP publisher UK. International writing panel. The unchanged original EJCTS PDF mirror is hosted by MATCVS, Malaysia; it does not change the document author or funding origin. Edwards corporate headquarters Irvine, California, US; specific supplied-device manufacturing origin unresolved. | Tier 2 documented society industry routes, with unresolved author chain; independent efficacy excluded. | C provisional. Original 109-page guideline and August 2026 correction checked. Detailed methodology, specialist review and explicit evidence grades aid attributed clinical use; society commercial routes, inaccessible author declarations and uncleared original-trial finances prevent a clean independent outcome verdict. Role: Current 2025 specialist care context with August2026 correction checked; C provisional, not independent efficacy. |
| NHLBI valve disease and pregnancy, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Pre-pregnancy assessment and prescription-safety context. |
| NHLBI valve disease definitions, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Additional original linked in condition-specific education or follow-up. |
| NHLBI budget | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHLBI Gift Fund | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHS national website funding policy | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 3 editorial and financial self-disclosure. | B provisional. Explicit funding policy; actual individual declarations and implementation not audited. Financial provenance only. |
| ESC funding and revenue model | ESC directly reports life-science and medtech partnership income alongside memberships, congresses, publishing and education. Its July 2026 policy manages industry remuneration and other interests; reporting a policy is not proof that all bias is removed. | France; ESC European Heart House, Sophia Antipolis; multinational professional society. | Tier 3 institutional self-disclosure; financially interested in its own governance description. | B provisional for stated revenue routes; C where relied on to certify its own clinical independence. Financial transparency supports checking; actual amounts, implementation and document allocations not audited. Financial provenance only. |
| ESC conflict management policy | ESC directly reports life-science and medtech partnership income alongside memberships, congresses, publishing and education. Its July 2026 policy manages industry remuneration and other interests; reporting a policy is not proof that all bias is removed. | France; ESC European Heart House, Sophia Antipolis; multinational professional society. | Tier 3 institutional self-disclosure; financially interested in its own governance description. | B provisional for stated revenue routes; C where relied on to certify its own clinical independence. Financial transparency supports checking; actual amounts, implementation and document allocations not audited. Financial provenance only. |
| EACTS current industry/charity grant and Edwards Foundation relationship | EACTS explicitly offers industry/charity-sponsored outreach grants and names Edwards Lifesciences Foundation for Every Heartbeat Matters; a separate industry-sponsorship contact is provided. Edwards confirms funding, product donations and matching-gift routes. EACTS annual revenue amounts, complete donor list, guideline allocation and individual author finances were not fully traced. This is a documented institutional relationship, not evidence that Edwards directly financed the valve guideline. | United Kingdom; EACTS House, Windsor, registered company and charity in England and Wales. Edwards corporate headquarters Irvine, California, United States; global manufacturing locations differ from grant or guideline jurisdiction. | Tier 3 institutional financial self-disclosure; society has a stake in its own governance description. | B provisional for documented relationships and registered contact; C if used to certify clinical independence. Direct named support improves transparency; amounts, contract terms, full donor and page/author chains remain unresolved. Financial provenance only. |
| EACTS industry sponsorship route | EACTS explicitly offers industry/charity-sponsored outreach grants and names Edwards Lifesciences Foundation for Every Heartbeat Matters; a separate industry-sponsorship contact is provided. Edwards confirms funding, product donations and matching-gift routes. EACTS annual revenue amounts, complete donor list, guideline allocation and individual author finances were not fully traced. This is a documented institutional relationship, not evidence that Edwards directly financed the valve guideline. | United Kingdom; EACTS House, Windsor, registered company and charity in England and Wales. Edwards corporate headquarters Irvine, California, United States; global manufacturing locations differ from grant or guideline jurisdiction. | Tier 3 institutional financial self-disclosure; society has a stake in its own governance description. | B provisional for documented relationships and registered contact; C if used to certify clinical independence. Direct named support improves transparency; amounts, contract terms, full donor and page/author chains remain unresolved. Financial provenance only. |
| EACTS registered jurisdiction and Windsor contact | EACTS explicitly offers industry/charity-sponsored outreach grants and names Edwards Lifesciences Foundation for Every Heartbeat Matters; a separate industry-sponsorship contact is provided. Edwards confirms funding, product donations and matching-gift routes. EACTS annual revenue amounts, complete donor list, guideline allocation and individual author finances were not fully traced. This is a documented institutional relationship, not evidence that Edwards directly financed the valve guideline. | United Kingdom; EACTS House, Windsor, registered company and charity in England and Wales. Edwards corporate headquarters Irvine, California, United States; global manufacturing locations differ from grant or guideline jurisdiction. | Tier 3 institutional financial self-disclosure; society has a stake in its own governance description. | B provisional for documented relationships and registered contact; C if used to certify clinical independence. Direct named support improves transparency; amounts, contract terms, full donor and page/author chains remain unresolved. Financial provenance only. |
| Edwards corporate/foundation funding and technology-donation routes | Edwards Lifesciences corporate/foundation self-disclosure. It describes charitable funding, technology donations, employee matching and annual recipients. Corporate device sales and reputation create a direct interest; no corporate clinical outcome claim is used as independent evidence. Foundation-wide donors, grant contract terms and specific product provenance were not audited. | United States; Edwards Lifesciences corporate global headquarters Irvine, California. The opened location page names US manufacturing and says manufacturing is multinational; a headquarters is not the origin of every implant. | Tier 4 maker-associated corporate/foundation self-disclosure; clinical outcome claims excluded. | D for clinical promotion; provisional B only for explicit self-reported addresses and funding routes cross-checked with EACTS. Commercial and reputational incentives remain. Financial provenance only. |
| Edwards global headquarters and manufacturing-location disclosure | Edwards Lifesciences corporate/foundation self-disclosure. It describes charitable funding, technology donations, employee matching and annual recipients. Corporate device sales and reputation create a direct interest; no corporate clinical outcome claim is used as independent evidence. Foundation-wide donors, grant contract terms and specific product provenance were not audited. | United States; Edwards Lifesciences corporate global headquarters Irvine, California. The opened location page names US manufacturing and says manufacturing is multinational; a headquarters is not the origin of every implant. | Tier 4 maker-associated corporate/foundation self-disclosure; clinical outcome claims excluded. | D for clinical promotion; provisional B only for explicit self-reported addresses and funding routes cross-checked with EACTS. Commercial and reputational incentives remain. Financial provenance only. |
Frequently asked questions
Is this the same as aortic stenosis? No. Leakage and restricted opening are different findings and can coexist. NHLBI valve anatomy and types, March2022.
Does it always require replacement? No. Cause, severity, symptoms, ventricular effects and aortic disease determine whether surveillance or an intervention assessment is appropriate. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Can normal exercise tolerance settle the follow-up question? No. Significant chronic leakage can affect ventricular size or function before a person recognizes a major limitation. Imaging and clinical review remain relevant. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Is a TAVI recommendation for stenosis automatically applicable? No. Pure regurgitation has different anatomy and device-selection issues; a specialist decision should explain those differences. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Sources and funding notes
- NHLBI valve anatomy and types, March2022 — Dated public anatomy and distinctions between stenosis, regurgitation and prolapse.
- NHLBI valve disease causes, March2022 — Dated public inherited and acquired contributor education.
- NHLBI valve disease symptoms, March2022 — Public symptom education; symptoms do not establish severity.
- NHLBI valve disease diagnosis, March2022 — Clinical investigation background; no self-diagnostic thresholds.
- NHLBI valve care background, March2022 — Dated public procedure/adverse-effect background; oversimplified tissue-valve anticoagulation wording not reproduced.
- NHS current national heart valve disease education — January 2025 national condition and emergency education; broad prolapse wording not reproduced.
- Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF — Current 2025 specialist care context with August2026 correction checked; C provisional, not independent efficacy.
- NHLBI valve disease and pregnancy, March2022 — Pre-pregnancy assessment and prescription-safety context.
- NHLBI valve disease definitions, March2022 — Additional original linked in condition-specific education or follow-up.
- NHLBI budget — Financial provenance only.
- NHLBI Gift Fund — Financial provenance only.
- NHS national website funding policy — Financial provenance only.
- ESC funding and revenue model — Financial provenance only.
- ESC conflict management policy — Financial provenance only.
- EACTS current industry/charity grant and Edwards Foundation relationship — Financial provenance only.
- EACTS industry sponsorship route — Financial provenance only.
- EACTS registered jurisdiction and Windsor contact — Financial provenance only.
- Edwards corporate/foundation funding and technology-donation routes — Financial provenance only.
- Edwards global headquarters and manufacturing-location disclosure — Financial provenance only.
Original clinical pages and their relevant financial disclosures were opened. The original 109-page 2025 ESC/EACTS valve guideline was read from MATCVS’s unchanged EJCTS/OUP PDF mirror, with its title, authors and DOI verified. The official August 6, 2026 correction was opened separately. The official author-declaration PDF returned 403 and was not read. Actual ESC, EACTS and Edwards financial-route disclosures were checked; separate institutional industry support does not establish direct industry financing of this document. Individual author and original-trial financial chains remain unresolved; clinical recommendations are C-provisional context. Clinical sources concentrate on US and English public education plus European professional guidance. This limits jurisdictional breadth: referral, implant availability and treatment systems vary, and no global access claim is inferred. Guidance, classification, emergency education and independent efficacy are distinct source roles. A full systematic review, complete society donor audit and author-by-author clearance of original treatment trials were not completed.
Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.